About MolecularMD
MolecularMD is a Healthcare company based in Portland (United States) founded in 2005, and was acquired by Icon in January 2019. It operates as a molecular diagnostics for oncology applications are provided by MolecularMD. MolecularMD has raised $16.07 million across 5 funding rounds from investors including ICON, Ballast Point Ventures and Nextech Invest. The company has 83 employees. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is MOLECULARMD CORP. Its competitors include Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Provider of molecular diagnostics for oncology applications. The company offers next-gen sequencing panels, molecular diagnostics for targeted therapy management in lung cancer, melanoma, gastrointestinal stromal tumors (GIST), and chronic myeloid leukemia (CML), and pathway analysis for tumor suppressor genes, mTOR and MEK pathways. In addition, MolecularMD also offers companion diagnostic development services; most notably, their testing evaluated the primary endpoint that led to FDA approval of Novartis nilotinib as first-line therapy for CML.
- Headquarters Portland, United States
- Employees 83
- SectorsHealthcare
- Phone•••• ••••
- Website molecularmd.com
- Social LinkedIn X
- Acquired by Icon (Jan 2019)
- Legal Name Molecularmd Corp.
Funding Insights of MolecularMD
MolecularMD has successfully raised a total of $16.07M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $2.07 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.07M
- Total Rounds 5
- Last Round Series B — $2.07M
- First Round $3M
(Oct 2009)
- Investors Count 2
All 5 funding rounds of MolecularMD with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $2.07M | Series B | – | – | – |
| Jul 2016 | $500,000 | Series B | – | – | – |
| May 2013 | $2.5M | Series B | – | – | – |
| Apr 2012 | $8M | Series B | – | Ballast Point Ventures, Nextech Invest | – |
| Oct 2009 | $3M | Series A | – | Ballast Point Ventures | – |
3 investors in total: 3 institutional.
Investors in MolecularMD
MolecularMD has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ICON, Ballast Point Ventures and Nextech Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Expansion capital is provided by Ballast Point Ventures to growing companies. | – | ballastpointventures.com | Tampa, United States | |
PE firm investing in the US | – | nextechinvest.com | Zurich, Switzerland | |
ICON plc is engaged in clinical research and drug development services. | 1990 | iconplc.com | Dublin, Ireland |
Investor details for MolecularMD
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of MolecularMD
4 dated milestones of MolecularMD across 14 years, from founding to its latest funding, stage changes and deals.
- Founded MolecularMD is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series B, of $2.1M.
- Exit Acquired by Icon.
Competitors of MolecularMD
MolecularMD has 9 listed competitors in our database, 9 of them funded. They include Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test |
Detailed competitors of MolecularMD
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MolecularMD
Websites that share an audience with MolecularMD (molecularmd.com).
Websites whose visitors overlap most with MolecularMD. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| roche.com | 100% | 1.3M | #42,219 | View details |
Top companies in Oncology
10 companies that operate in the same segment as MolecularMD (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Molecularmd
Complete news archive for MolecularMD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MolecularMD
MolecularMD was founded in 2005 and raised its 1st funding round 4 years after it was founded.
MolecularMD is headquartered in Portland, United States. It is registered at Portland, Oregon, United States.
MolecularMD is a funded company, having raised a total of $16.07M across 5 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Oct 2009.
MolecularMD has 83 employees.
Provider of molecular diagnostics for oncology applications. The company offers next-gen sequencing panels, molecular diagnostics for targeted therapy management in lung cancer, melanoma, gastrointestinal stromal tumors (GIST), and chronic myeloid leukemia (CML), and pathway analysis for tumor suppressor genes, mTOR and MEK pathways. In addition, MolecularMD also offers companion diagnostic development services; most notably, their testing evaluated the primary endpoint that led to FDA approval of Novartis nilotinib as first-line therapy for CML.
MolecularMD's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
MolecularMD has 3 investors. Key investors include ICON, Ballast Point Ventures, and Nextech Invest.
MolecularMD operates through Molecularmd Corp..
Yes. MolecularMD was acquired by Icon in January 2019.